Focus: Assembly Biosciences is a public biotech company focused on small-molecule antivirals for infectious diseases and neurology, with a lean 51-200 person team headquartered in South San Francisco. The company is in early-to-mid stage clinical development with no approved products.
Profile data last refreshed 19m ago · AI intelligence enriched 2w ago
Assembly is a high-risk, high-reward play for scientists who want early clinical involvement in antivirals but must tolerate acute cash constraints and execution uncertainty.
Help build intelligence for Assembly Biosciences
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Assembly Biosciences's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
+1 more
H.C. Wainwright Keeps Their Buy Rating on NRX Pharmaceuticals (NRXP) - The Globe and Mail
H.C. Wainwright Keeps Their Buy Rating on NRX Pharmaceuticals (NRXP) The Globe and Mail
Adial broadens pipeline with Azora acquisition and up to $64 million financing - The Pharma Letter
Adial broadens pipeline with Azora acquisition and up to $64 million financing The Pharma Letter
Newron Pharmaceuticals SpA (NWPHF) Gets a Buy from H.C. Wainwright - The Globe and Mail
Newron Pharmaceuticals SpA (NWPHF) Gets a Buy from H.C. Wainwright The Globe and Mail
Assembly Biosciences Teases Gilead HSV-2 Decision, Liver Disease Data Ahead - Yahoo Finance
Assembly Biosciences Teases Gilead HSV-2 Decision, Liver Disease Data Ahead Yahoo Finance
Assembly Biosciences Eyes Gilead HSV Plan as ABI-6250 Liver Pipeline Expands - TradingView
Assembly Biosciences Eyes Gilead HSV Plan as ABI-6250 Liver Pipeline Expands TradingView
8-K Filing: ASSEMBLY BIOSCIENCES, INC. (ASMB) (CIK 0001426800) — 8-K
8-K
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Chronic Hepatitis B Finite Treatment: Similar and Different Concerns With New Drug Classes.
Long-term open-label vebicorvir for chronic HBV infection: Safety and off-treatment responses.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo